Patients with levodopa-responsive and levodopa-resistant tremors exhibit differing preferences on the type of deep brain stimulation administered to control motor function in Parkinson disease.
The efficacy of deep brain stimulation (DBS) to improve motor function in Parkinson disease (PD) may be related with patient responsiveness to levodopa and the type of DBS administered, according to study findings published in Frontiers in Human Neuroscience.
As a neurosurgical treatment for motor fluctuations and dyskinesia in patients with advanced PD, there are 2 main types of DBS studied in the disease: surgery within the subthalamic nucleus (STN) and globus pallidus interna (GPi). Noted as being similar and consistent, randomized clinical trials have reported subtle differences in the efficacy of both approaches.
Moreover, levodopa responsiveness has emerged as a significant, yet controversial factor in determining those who may benefit from DBS surgery. Described as the levodopa challenge test, studies have reported differing results on whether this preoperative assessment could serve as a predictor of DBS efficacy on motor function in PD.
“Most previous studies only enrolled patients undergoing STN-DBS, while the value of preoperative levodopa responsiveness as a predictor for GPi-DBS responsiveness has not been adequately studied,” expanded researchers.
Aiming to describe the value of levodopa responsiveness on predicting motor outcomes of patients with PD following the levodopa challenge test, researchers conducted a retrospective study of 38 patients with idiopathic PD who underwent STN-DBS (n = 18) or GPi-DBS (n = 20) surgery.
Researchers utilized the Movement Disorder Society Unified Parkinson Disease Rating Scale-Motor Part III (MDS UPDRS-III) to examine motor function prior to surgery and at the last follow-up (median follow-up duration, 7 months), with levodopa responsiveness and type of DBS administration noted.
In their assessment, the short-term predictive value of the levodopa challenge test was identified in 4 key areas for the motor outcome of both DBS approaches in PD:
Specifically, via Pearson’s correlation analysis (R2), researchers found a positive correlation between preoperative levodopa challenge responsiveness and GPi-DBS responsiveness on the total score (R2, 0.283; P = 0.016), but not on the non-tremor total score (R2, 0.158; P = .083) of MDS UPDRS-III. This correlation remained significant after controlling for age at the time of surgery, which was not found for patients who underwent STN-DBS.
For those who underwent STN-DBS, a positive correlation between preoperative levodopa challenge responsiveness and STN-DBS responsiveness was found for the non-tremor total score (R2, 0.290; P = .021), but not on the total score (R2, 0.130; P = .141) of MDS UPDRS-III, inverse to that found for those given GPi-DBS.
Researchers note that the small sample size, short-term follow-up, non-randomized group allocation, and retrospective design serve as the main limitations of the study, which they say warrants a more extensive, randomized, prospective long-term study to confirm findings.
Reference
Lin Z, Zhang X, Wang L, et al. Revisiting the L-Dopa Response as a Predictor of Motor Outcomes After Deep Brain Stimulation in Parkinson’s Disease. Front Hum Neurosci. Published online February 4, 2021. doi:10.3389/fnhum.2021.604433
Major Study Expands in Hopes to Cure Parkinson Disease
April 19th 2022April is Parkinson’s Disease Awareness month, and on this episode of Managed Care Cast, we take a look at the Parkinson's Progression Markers Initiative (PPMI), a study from the Michael J. Fox Foundation for Parkinson's Research (MJFF). The multicenter, international study aims to end Parkinson disease, which is expected to double worldwide by 2040, to more than 14 million people.
Listen
Certain Patient Groups Continue to Be Underrepresented in PD Studies in the Netherlands
February 4th 2023With greater attention being paid to the heterogenous patient population, researchers questioned whether this has resulted in a more diverse group of patients included in Parkinson disease (PD) studies in the Netherlands.
Read More
An Inside Look at Innovations by MJFF to Assist the Parkinson Community Amid the COVID-19 Pandemic
May 26th 2020On this episode of Managed Care Cast, we speak with Rachel Dolhun, MD, vice president of Medical Communications at The Michael J. Fox Foundation for Parkinson Research, about recent innovations by The Michael J. Fox Foundation to assist patients and families of patients with Parkinson disease in adjusting to this new normal.
Listen
Motor Symptoms May Occur 3 Years Before Parkinson Disease Diagnosis, Study Says
January 20th 2023Trouble with balance and holding objects above one's head were just a few of the problems reported by patients 3 years before they received a formal Parkinson disease diagnosis, according to a recent study.
Read More